Discover MabDesign

MabDesign, the French association of the industrial sector of biomedicines, aims to support, structure, federate and increase the visibility of the industrial sector of biological medicines.
carl-newton-2C6kAtCXf6U-unsplash

Access our network

Join the MabDesign network to take advantage of all the advantages and opportunities offered.
casey-horner-9vf1uj6i6Ww-unsplash

Develop your skills

Consult and register for our next training courses in order to acquire new expertise.
smartworks-coworking-Uz8THWPXwhI-unsplash

Explore our business services

The field of therapeutic antibodies and immunotherapy is growing rapidly. The French industrial ecosystem is rich in innovative companies with considerable potential. MabDesign’s mission is to support them in their development in France and abroad.
arlington-research-kN_kViDchA0-unsplash

Upcoming events

Add your title here

23
Feb.
23-26 February 2026
Partner Event
10
Mar.
March 10-12 2026
Partner Event
17
Mar.
17 March 2026
Partner Event
17
Mar.
March 17-18, 2026
Partner Event
23
Mar.
March 23-25, 2026
Partner Event
25
Mar.
March 25-26, 2026
Partner Event

Our News

2009_ViruSure_Logo_4C

ViruSure - new international member

12 January 2026
As a leading CRO specializing in virus and prion safety testing, ViruSure provides comprehensive biosafety solutions for biopharmaceuticals and ATMPs.
SOT_LOGO_PRINCIPAL

SOTERIA BIO - new member

12 January 2026
SoteriaBio développe une plateforme de formulation brevetée permettant une distribution ciblée de biomolécules dans les voies respiratoires pour le traitement des maladies inflammatoires chroniques.
Logo-Detera-degrade-RVB-principal

DETERA Therapeutics - new member

12 January 2026
DETERA est une société deeptech qui développe des solutions disruptives pour le traitement des maladies rénales rares.
cti_biotech_logo

CTIBIOTECH - new member

12 January 2026
CTIBIOTECH is a pioneering company based in Lyon (France), specializing in the development of advanced human tissues for biomedical research and the pharmaceutical industry, and for future therapies.

OUR BOARD OF DIRECTORS